<DOC>
	<DOCNO>NCT01683864</DOCNO>
	<brief_summary>The gastric carcinoma one four common tumor occur worldwide . The advanced phase characterize metastasis pose poor prognosis survival . In 20 % -30 % gastric carcinoma tumor spread abdominal cavity , lead metastasis wall peritoneal cavity . This known peritoneal carcinomatosis five-year survival rate le 2 % . Even R0 resection localize gastric carcinoma five-year survival rate 40 % , least relapse form peritoneal metastasis common occurrence . Patients gastric carcinoma yet diagnose metastasis , show free tumor cell cytology preoperative laparoscopy neoadjuvant chemotherapy gastrectomy , 80 % risk develop peritoneal carcinomatosis within one year , stand strong contrast 40 % risk patient negative cytology . In study present ( group A ) therapeutic hyperthermic intraperitoneal chemoperfusion ( HIPEC , literature also know HIIC ( heat intraoperative intraperitoneal chemotherapy ) IPHC ( intraperitoneal chemohyperthermia ) ) mitomycin c cisplatin administer follow gastrectomy patient gastric carcinoma free tumor cell cytology diagnose preoperative laparoscopy comparison ( group B ) solely gastrectomy patient gastric carcinoma also free tumor cell diagnose cytology preoperative laparoscopy . A randomization perform group A B . Patients gastric carcinoma ( TNM Stage ≥ T2 &lt; T4 ) without proven metastasis ( TNM stage M0 ) , without involve regional lymph node ( TNM stage +N/-N ) positive cytology preoperative abdominal lavage include . Exclusion criterion extend disease inoperable tumor . This study already permit local ethic commission German Federal Institute Drugs Medical Devices ( BfArM ) ( EudraCT-Nr . : 2011-004405-25 / Study code : HIPEC_Stomach ) initiate August 2012 .</brief_summary>
	<brief_title>Randomized Controlled Trial Prevent Peritoneal Seeding Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically proven gastric adenocarcinoma : uT1 , uT2 , uT3 , Nx , M0 2 . No prior chemotherapy 3 . Patients full age , independent gender ECOG ≤ 2 4 . No dissemination tumor confirm CT lung abdomen . 5 . Signed Consent form Patient agree investigation 6 . Leucocytes &gt; 3.000/µl 7 . Thrombocytes &gt; 100.000/µl 8 . Creatinine ≤ 1.5mg/dl Clearance &gt; 60 ml/min 9. informed consent patient 10. normal ejectionfraction heart 1 . Dissemination tumor nonresectable primary tumor 2 . Malignant secondary disease &lt; 5 year past ( Exception : insitucarcinoma cervix appropriately treat basal cell carcinoma skin ) 3 . Patient full age 4 . Inflammatory chronic bowel disease 5 . Inclusion patient different study 6 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>